Learn / Biostatistics / Statistics in clinical trials and evidence synthesis
Intention-to-treat, per-protocol and missing data
14 minute read · 6-question quiz
What you will learn
Define intention-to-treat (ITT), modified ITT and per-protocol analyses and choose between them
Explain how non-adherence and missing data bias a trial and what the estimand framework adds
Describe the options for handling missing outcome data and why last-observation-carried-forward is discouraged
Randomisation creates comparable groups, but only if they stay comparable. In practice participants stop taking treatment, switch arms, are found ineligible or vanish. How these people are handled in the analysis decides whether the trial's comparison is still protected by randomisation.
Analysis populations
| Population | Who is analysed | Strength | Weakness |
| Intention-to-treat (ITT) | Everyone randomised, in the arm they were assigned, whatever happened next | Preserves randomisation; unbiased for the effect of a treatment policy; the primary analysis in superiority trials | Dilutes the effect when many do not take treatment |
| Modified ITT (mITT) | ITT minus a few pre-defined exclusions (never received any dose, found ineligible after randomisation due to a blinded process) | Practical | Open to abuse; define in the protocol |
| Per-protocol (PP) | Only those who followed the protocol adequately | Closer to the effect of taking the drug | Breaks randomisation; compares unlike groups |
| As-treated | By the treatment actually received | Describes safety | Treatment received is not random |
The estimand framework (ICH E9 R1)
Modern regulators ask trial teams to define the estimand: the exact quantity the trial estimates. It has five attributes: the population, the treatment, the outcome variable, the handling of intercurrent events (stopping treatment, switching, death), and the summary measure. Different questions give different estimands. 'What is the effect if everyone takes the drug as directed?' differs from 'What is the effect of prescribing it?' Strategies for intercurrent events include treatment-policy (ITT), hypothetical (as if the event had not happened), composite, while-on-treatment and principal-stratum. State the estimand in the protocol and align the analysis with it.
Missing data
Missing outcome data are inevitable and damaging. The mechanism matters.
- MCAR (missing completely at random): unrelated to anything. Rare in practice; complete-case analysis is unbiased but loses power.
- MAR (missing at random): missingness depends on observed data (older patients miss more visits, but within age groups it is random). Handle with multiple imputation or likelihood-based models.
- MNAR (missing not at random): missingness depends on the unobserved value itself (people with worse outcomes drop out). No analysis fully fixes this; use sensitivity analyses.
Summary
ITT analyses everyone as randomised and is the primary analysis for superiority trials.
Per-protocol analysis breaks randomisation and can exaggerate benefit.
Define the estimand, including how intercurrent events such as stopping treatment are handled.
Missing data are MCAR, MAR or MNAR; use multiple imputation or mixed models, with sensitivity analyses.
Avoid LOCF and mean substitution; prevent missingness through trial conduct.
Check your understanding
Draft study guide. Spotted an error or something unclear? Tell us at hello@scintria.com. This is educational material, not clinical or regulatory advice.